摘要
目的 :观察莫沙必利对肝硬化胃排空延迟的疗效。方法 :6 0例肝硬化胃排空延迟的患者随机分为A、B两组 ,A组 30例 ,每日 3餐前 30min口服莫沙必利 5mg;B组 30例 ,3餐前 30min口服多潘立酮 10mg。采用B超测定胃排空机能。治疗 2周后了解病人上消化道症状改善情况 ,并复查B超了解胃液体排空情况。结果 :两组病人服药后上消化道症状均有所改善 ,莫沙必利对早饱、腹胀的总有效率高于多潘立酮 ,有显著差异 (P <0 .0 5 ) ;两组治疗后胃排空率较治疗前显著增加 (P <0 .0 1) ,且A组高于B组 ,有显著差异 (P <0 .0 5 )。结论 :莫沙必利是治疗肝硬化胃排空延迟的有效、安全药物 ,疗效优于多潘立酮。
Objective: To assess the effect of Mosa pri de citrate tablets on gastric emptying in cirrhotic patients.Methods: Sixty patients with liver cirrhosis were enrolled and randomly divide d into two groups. Patients in group A (30 cases) were administered Mosapride cit rate (5mg 3/d p.o, 30 mins before the meal); the other 30 patients in group B w ere administered Domperidone (10mg 3/d p.o, 30 mins before the meal).An B-type ultrasonic method was used for the estimation of gastric emptying before and aft er treatment. Observe the upper gastric symptom and access the emptying ability of gastric after 2 weeks of treatment.Results: Symptoms of u pper gastrointestinal of both groups were improved. The total effective rates of mosapride in treating early satiety, epigastric fullness were higher than that of domperidone(P<0.05).Gastric emptying rate of both groups increased signif icantly(P<0.01). Furthermore, there was significant difference between group A and group B in gastric emptying rate (P<0.05).Conclusion: Mosapride citrate tablets is safe and effective in the treatment of delayed g astric emptying of liver cirrhosis patients, which is even better than Domperido ne.
出处
《中国临床医学》
2004年第6期1018-1019,共2页
Chinese Journal of Clinical Medicine
